$10.85
Dynavax Technologies Corporation is a drug manufacturers - specialty & generic business based in the US. Dynavax Technologies Corporation shares (DVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Dynavax Technologies Corporation employs 408 staff and has a trailing 12-month revenue of around $249.7 million.
What's in this guide?
- DVAX shares summary
- Compare share dealing platforms
- Is DVAX stock a buy or sell?
- Stock performance over time
- Are DVAX shares over-valued?
- Dynavax Technologies Corporation's financials
- How volatile are DVAX shares?
- Does Dynavax Technologies Corporation pay a dividend?
- Have DVAX shares ever split?
- Other common questions
Our top picks for where to buy Dynavax Technologies Corporation stock
How to buy Dynavax Technologies Corporation stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – DVAX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Dynavax Technologies Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Dynavax Technologies Corporation stock price (NASDAQ: DVAX)
Use our graph to track the performance of DVAX stocks over time.Dynavax Technologies Corporation shares at a glance
Latest market close | $10.86 |
---|---|
52-week range | $9.74 - $15.15 |
50-day moving average | $11.04 |
200-day moving average | $12.25 |
Wall St. target price | $24.50 |
PE ratio | 86.3077 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.13 |
Is it a good time to buy Dynavax Technologies Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Dynavax Technologies Corporation price performance over time
Historical closes compared with the close of $10.86 from 2024-09-04
1 week (2024-08-29) | -3.55% |
---|---|
1 month (2024-08-05) | 7.85% |
3 months (2024-06-05) | -10.25% |
6 months (2024-03-05) | -13.60% |
1 year (2023-09-05) | -23.68% |
---|---|
2 years (2022-09-02) | -3.12% |
3 years (2021-09-03) | 17.68 |
5 years (2019-09-05) | 144.04% |
Is Dynavax Technologies Corporation stock undervalued or overvalued?
Valuing Dynavax Technologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dynavax Technologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dynavax Technologies Corporation's P/E ratio
Dynavax Technologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 86x. In other words, Dynavax Technologies Corporation shares trade at around 86x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Dynavax Technologies Corporation financials
Revenue TTM | $249.7 million |
---|---|
Operating margin TTM | 10.03% |
Gross profit TTM | $448.2 million |
Return on assets TTM | -0.79% |
Return on equity TTM | 2.82% |
Profit margin | 6.88% |
Book value | $4.91 |
Market Capitalization | $1.5 billion |
TTM: trailing 12 months
Dynavax Technologies Corporation share dividends
We're not expecting Dynavax Technologies Corporation to pay a dividend over the next 12 months.
Have Dynavax Technologies Corporation's shares ever split?
Dynavax Technologies Corporation's shares were split on a 1:10 basis on 9 November 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dynavax Technologies Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dynavax Technologies Corporation shares which in turn could have impacted Dynavax Technologies Corporation's share price.
Dynavax Technologies Corporation share price volatility
Over the last 12 months, Dynavax Technologies Corporation's shares have ranged in value from as little as $9.74 up to $15.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dynavax Technologies Corporation's is 1.276. This would suggest that Dynavax Technologies Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Dynavax Technologies Corporation overview
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc. ; Clover Biopharmaceuticals (Hong Kong) Co. , Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt.
Frequently asked questions
nullWhat percentage of Dynavax Technologies Corporation is owned by insiders or institutions?
Currently 0.336% of Dynavax Technologies Corporation shares are held by insiders and 102.478% by institutions. How many people work for Dynavax Technologies Corporation?
Latest data suggests 408 work at Dynavax Technologies Corporation. When does the fiscal year end for Dynavax Technologies Corporation?
Dynavax Technologies Corporation's fiscal year ends in December. Where is Dynavax Technologies Corporation based?
Dynavax Technologies Corporation's address is: 2100 Powell Street, EmeryVille, CA, United States, 94608 What is Dynavax Technologies Corporation's ISIN number?
Dynavax Technologies Corporation's international securities identification number is: US2681582019 What is Dynavax Technologies Corporation's CUSIP number?
Dynavax Technologies Corporation's Committee on Uniform Securities Identification Procedures number is: 268158102
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question